Antibodies for Poly-Agonist Analysis: Tirzepatide and Retatrutide

From Single to Multiple Targets

Although GLP-1R agonists have revolutionized metabolic care, their efficacy is ultimately limited by dose-dependent gastrointestinal side effects that restrict further therapeutic optimization. To transcend the biological limitations of single-axis stimulation, contemporary drug design has shifted toward unimolecular poly-agonism. By integrating GLP-1R signaling with GIPR (and subsequently GCGR) activation, next-generation therapeutics leverage distinct physiological axes:

Fig. 1 Mechanisms of action of GIP, GLP-1 and their agonists. (Bass et al. 2023).

GLP-1R Activation: Enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite through central nervous system signaling.

GIPR Activation: Synergizes with GLP-1 to promote insulin secretion while improving insulin sensitivity and adipose tissue function. Importantly, central GIPR signaling may reduce the gastrointestinal side effects associated with GLP-1R activation.

GCGR Activation: Increases energy expenditure by stimulating thermogenesis and hepatic lipid oxidation. When balanced with GLP-1R and GIPR co-activation, glucagon's hyperglycemic effects are offset, allowing its lipolytic and weight-loss benefits to be fully utilized, while also improving hepatic steatosis.

Retatrutide

Retatrutide represents a major advance in single-peptide engineering: a unimolecular triple agonist configured to simultaneously engage GIPR, GLP-1R, and GCGR. Retatrutide incorporates N-terminal GIP-derived elements (notably Tyr1 and Gln3) to retain insulinotropic activity while maintaining compatibility with GLP-1R and GCGR binding requirements, including key positional features such as Tyr1 substitution for glucagon His1 and structural alignment at positions like Thr7 and Asp9 for GLP-1R interaction. Proteolytic stability is enhanced through incorporation of Aib at positions 2 and 20 and α-methyl-leucine at position 13, which collectively increase helicity and reduce enzymatic degradation. Similar to Tirzepatide, Retatrutide is lipidated at Lys17 with a C20 fatty diacid via a γ-Glu–AEEA₂ linker, promoting albumin binding and enabling an extended half-life of ~6 days to support once-weekly dosing.

Preclinical drug development, pharmacokinetics (PK/PD), bioequivalence profiling, and in situ tissue mapping rely fundamentally on antibody-based detection methods. Researchers need analytical tools designed specifically for this new generation of drugs. Creative Diagnostics has developed high quality Anti-Tirzepatide and Retatrutide antibodies for quantitative analysis. The following validation data illustrates the performance of these antibodies across various experimental platforms, providing a baseline for their integration into your metabolic study workflows.